Received Mar 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
perimyocarditis; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A male patient received BNT162b2 (BNT162B2), in Jun2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1), for COVID-19 immunization. The following information was reported: MYOPERICARDITIS (medically significant), outcome "unknown", described as "perimyocarditis". The event "perimyocarditis" required physician office visit. The patient (reporter's son) was diagnosed with perimyocarditis after receiving his second Pfizer covid vaccine in Jun2021. He was in [Withheld] and has to follow up yearly with a cardiologist. He is entering college this fall. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.